Neuroinflammation in Alzheimer's Disease

Migration, Crosslink

📖

Neuroinflammation in Alzheimer's Disease

active

wiki page Created: 2026-04-02T07:20:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-alzheimers-neuroinflamma

📖 Wiki Page

mechanism3061 wordssynced 2026-04-02

Neuroinflammation in Alzheimer's Disease

Neuroinflammation is now recognized as a central driver of Alzheimer's disease (AD) pathogenesis, functioning not merely as a secondary consequence of amyloid-beta (Aβ) and tau pathology but as an active, self-perpetuating contributor to disease progression. This pathway hub synthesizes current understanding of the neuroinflammatory cascade in AD, spanning from initial microglial activation through chronic cytokine storm, astrocyte reactivity, blood-brain barrier (BBB) dysfunction, and the bidirectional interplay between inflammation and protein aggregation. The page integrates molecular mechanisms, genetic evidence, therapeutic implications, and biomarkers, with cross-links to dedicated pages for deeper exploration.

Overview

Alzheimer's disease is characterized by two classical pathological hallmarks: extracellular amyloid plaques composed of Aβ peptides and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated [tau protein](/proteins/map-tau-protein). However, abundant evidence now demonstrates that chronic neuroinflammation — manifested through persistent activation of microglia and astrocytes, elevated pro-inflammatory cytokines, complement system engagement, and peripheral immune infiltration — is a third core pathological feature that interacts bidirectionally with both amyloid and tau pathology[@heneka2017].

...

Neuroinflammation in Alzheimer's Disease

Neuroinflammation is now recognized as a central driver of Alzheimer's disease (AD) pathogenesis, functioning not merely as a secondary consequence of amyloid-beta (Aβ) and tau pathology but as an active, self-perpetuating contributor to disease progression. This pathway hub synthesizes current understanding of the neuroinflammatory cascade in AD, spanning from initial microglial activation through chronic cytokine storm, astrocyte reactivity, blood-brain barrier (BBB) dysfunction, and the bidirectional interplay between inflammation and protein aggregation. The page integrates molecular mechanisms, genetic evidence, therapeutic implications, and biomarkers, with cross-links to dedicated pages for deeper exploration.

Overview

Alzheimer's disease is characterized by two classical pathological hallmarks: extracellular amyloid plaques composed of Aβ peptides and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated [tau protein](/proteins/map-tau-protein). However, abundant evidence now demonstrates that chronic neuroinflammation — manifested through persistent activation of microglia and astrocytes, elevated pro-inflammatory cytokines, complement system engagement, and peripheral immune infiltration — is a third core pathological feature that interacts bidirectionally with both amyloid and tau pathology[@heneka2017].

The innate immune system of the brain is primarily represented by [microglia](/cell-types/microglia), which constitute approximately 10–15% of all brain cells and serve as the resident macrophages of the central nervous system (CNS)[@ransohoff2016]. Under normal conditions, microglia exist in a surveillant state, continuously scanning their microenvironment through dynamic process motility and rapidly responding to pathological insults. In AD, this surveillant state transitions to a chronic activated state characterized by morphological changes, transcriptional reprogramming, and altered functional responses that initially may be protective but become progressively detrimental[@hepner2015].

The genetic architecture of AD provides compelling evidence for neuroinflammation as a disease driver. GWAS have identified multiple immune-related risk loci including [TREM2](/genes/trem2), [CD33](/genes/cd33), [PLCG2](/genes/plcg2), [ABI3](/genes/abi3), and [INPP5D](/entities/inpp5d)[@sims2017], collectively implicating microglial dysfunction as a key contributor to late-onset AD pathogenesis.

Microglial Activation in Alzheimer's Disease

The Microglial Surveillance State

In the healthy brain, microglia exist in a surveillant (resting) state characterized by a small cell body with highly ramified processes that continuously sample the extracellular space[@patterson2018]. This surveillance function is mediated by numerous pattern recognition receptors (PRRs), ion channels, and signaling molecules that enable rapid detection of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). The transformation from surveillant to activated microglia involves dramatic morphological changes (amoeboid shape, enlarged soma, retracted processes), transcriptional reprogramming, and functional shifts in phagocytosis, cytokine production, and antigen presentation.

Pattern Recognition Receptors in AD

Microglia detect Aβ through multiple PRR families:

[TLR2 and TLR4](/entities/toll-like-receptor-signaling) (Toll-like receptors) recognize Aβ and initiate MyD88-dependent signaling cascades leading to NF-κB activation and pro-inflammatory cytokine transcription[@isin2019]. TLR4 activation by Aβ induces production of IL-1β, TNF-α, and IL-6, driving the inflammatory cascade forward.

[TREM2](/genes/trem2) (Triggering Receptor Expressed on Myeloid Cells 2) is a critical microglial receptor for Aβ recognition, lipid binding, and phagocytosis[@colonna2016]. TREM2 is expressed exclusively on microglia in the CNS and signals through the adaptor protein DAP12 (TYROBP) to activate PI3K and CSF1R pathways. Rare loss-of-function variants in TREM2 significantly increase AD risk (3–5-fold for R47H variant), and TREM2 deficiency in mouse models results in reduced microglial clustering around plaques, increased plaque burden, and worsened cognitive outcomes[@jonsson2013].

[RAGE](/entities/rage-signaling-neurodegeneration) (Receptor for Advanced Glycation End-products) binds Aβ and contributes to microglial activation, ROS production, and NF-κB signaling[@yan2012]. RAGE-Aβ interactions at the BBB also facilitate Aβ entry into the brain, creating a vicious cycle.

Disease-Associated Microglia (DAM)

Single-cell RNA sequencing has identified multiple microglial states in AD brains[@zhou2021]:

Homeostatic microglia: Express P2RY12, TMEM119, CX3CR1 — maintain surveillance

DAM (Disease-Associated Microglia): Upregulate TREM2, APOE, CD74, LPL — cluster at plaques; depend on TREM2 for their formation

IFN-responsive microglia: Express interferon-stimulated genes — respond to viral or immune challenges

Proliferative microglia: Express cell cycle genes — indicate microglial expansion

Aging-associated microglia (AAM)/Inflammaging: Upregulate age/inflammation signatures, particularly prominent in APOE ε4 carriers[@isin2022]

The DAM program represents a neuroprotective response that promotes Aβ clearance but becomes dysregulated over time. Single-nucleus transcriptomics reveals that TREM2-dependent DAM signatures are enriched in early-stage AD, while TREM2-independent interferon signatures predominate in advanced disease[@wolf2023].

APOE and Microglial Function

[APOE](/proteins/apoe) (apolipoprotein E) is produced by astrocytes and microglia and plays central roles in lipid transport and Aβ binding[@yin2017]. The APOE ε4 allele, the strongest genetic risk factor for late-onset AD after TREM2, significantly impairs microglial Aβ clearance efficiency. APOE ε4 carriers demonstrate reduced microglial phagocytic capacity, enhanced inflammatory responses, and altered lipid metabolism compared to APOE ε3 carriers. TREM2 and APOE pathways intersect at the level of microglial lipid metabolism and inflammatory signaling, creating a genetically supported mechanism for immune dysfunction in AD.

Phagocytic Dysfunction

One of the critical functions of microglia is Aβ clearance through phagocytosis[@wang2015]. This process involves receptor-mediated recognition (TREM2, TLRs, CD36), internalization into phagosomes, and lysosomal degradation. In AD, chronic exposure to Aβ and inflammatory cytokines leads to a "burnout" phenotype characterized by impaired phagocytic capacity, lysosomal dysfunction, and persistent inflammatory mediator production — paradoxically reducing clearance while maintaining neurotoxic inflammation.

TREM2 Signaling Pathways

TREM2 Structure and Ligands

TREM2 is a type I transmembrane receptor belonging to the immunoglobulin superfamily. Its extracellular domain binds diverse ligands including Aβ, lipids, apolipoproteins (APOE, APOJ), and phosphatidylserine暴露 on apoptotic cells[@colonna2016]. The cytoplasmic tail lacks signaling motifs and relies on the adaptor protein DAP12 (TYROBP) for signal transduction.

Downstream Signaling Cascades

TREM2-DAP12 signaling activates multiple pathways:

PI3K/Akt pathway: Promotes microglial survival and anti-inflammatory responses[@wang2015]
CSF1R pathway: Regulates microglial proliferation and homeostatic maintenance[@wang2020]
Syk kinase activation: Mediates cytoskeletal reorganization and phagocytosis
NF-κB modulation: Can shift microglial phenotype toward neuroprotection

The balance between these pathways determines whether TREM2 activation promotes beneficial Aβ clearance or excessive inflammation.

TREM2 Therapeutic Approaches

Multiple therapeutic strategies targeting TREM2 are in development[@schneeberger2019]:

Agonist antibodies: Enhance TREM2 signaling to boost microglial Aβ clearance
Gene therapy: Viral delivery of functional TREM2 to complement loss-of-function variants
Soluble TREM2 (sTREM2): biomarker reflecting microglial activation; CSF sTREM2 levels correlate with disease stage and predict progression

TREM2 gene therapy approaches have shown promise in preclinical models, reducing amyloid pathology through enhanced microglial clustering and phagocytosis.

The Complement Cascade in AD

Classical Complement Activation

The complement system is heavily implicated in AD pathogenesis through both synaptic pruning and direct neurotoxicity[@stevens2007]. The classical complement cascade is activated by C1q binding to Aβ plaques and damaged synapses, leading to C3 convertase formation and downstream effector generation.

C1q localizes to synapses and tags them for complement-mediated elimination. In AD, excessive C1q tagging leads to abnormal synaptic pruning that correlates with cognitive decline[@hong2016].

C3 and its cleavage fragments (C3a, C3b) are upregulated in reactive astrocytes and microglia. C3a drives neuroinflammation through anaphylatoxin receptor signaling; C3b mediates opsonization and microglial phagocytosis of tagged synapses.

C5a (membrane attack complex pathway) promotes neuroinflammation and may directly damage neurons through the membrane attack complex (MAC).

Microglial Synapse Elimination

The complement system mediates synaptic loss through a well-characterized pathway[@hong2016]: C1q tags synapses, C3 is deposited, microglia recognize C3-tagged synapses via CR3 (complement receptor 3), and complement-mediated phagocytosis eliminates the synapse. This mechanism normally operates during development for circuit refinement but becomes pathologically activated in AD, contributing to early synaptic loss even before neuronal death.

Cytokine Network in AD Neuroinflammation

Pro-Inflammatory Cytokines

Activated microglia and astrocytes release a network of pro-inflammatory mediators that drive and amplify neuroinflammation:

| Cytokine | Primary Source | Key Effects in AD | CSF/Brain Levels |
|----------|---------------|-------------------|-----------------|
| IL-1β | Microglia, astrocytes | Promotes Aβ production, tau phosphorylation, synaptic dysfunction | Elevated |
| TNF-α | Microglia, neurons | Neurotoxicity, BBB disruption, enhances Aβ toxicity | Elevated |
| IL-6 | Microglia, astrocytes | Glial activation, impairs hippocampal plasticity | Elevated |
| IL-18 | Microglia | Inflammasome product, promotes IFN-γ responses | Elevated |
| CXCL1/KC | Astrocytes | Neutrophil recruitment, amplifies inflammation | Elevated |
| CCL2/MCP-1 | Astrocytes, microglia | Monocyte and microglial recruitment to plaques | Elevated |

IL-1β and the Inflammasome Connection

IL-1β is among the most studied cytokines in AD pathogenesis[@lizio2018]. Elevated in both brain tissue and CSF, IL-1β levels correlate with disease severity. IL-1β creates feed-forward loops by:

Promoting amyloid precursor protein (APP) processing toward Aβ production
Enhancing tau phosphorylation via GSK-3β and CDK5
Inducing production of other cytokines (IL-6, TNF-α)
Contributing directly to synaptic dysfunction and memory impairment

The Cytokine Storm Concept

The combination of elevated IL-1β, TNF-α, and IL-6 creates a "cytokine storm" effect in the AD brain that contributes to:

Accelerated tau pathology through kinase activation
Excitotoxicity through glutamate receptor modulation
Synaptic loss through complement and direct toxicity
BBB dysfunction and peripheral immune infiltration
Neuronal apoptosis through multiple pathways

NLRP3 Inflammasome in AD

Inflammasome Activation by Aβ

The [NLRP3 inflammasome](/mechanisms/nlrp3-inflammasome) is a cytosolic protein complex that catalyzes caspase-1 activation and maturation of IL-1β and IL-18[@heneka2013]. Aβ activates the NLRP3 inflammasome through two signals:

Signal 1 (priming): Aβ binding to TLRs and RAGE induces NF-κB-dependent transcription of NLRP3, pro-IL-1β, and pro-IL-18.

Signal 2 (activation): Aβ particles are phagocytosed, causing lysosomal damage and release of cathepsins; intracellular potassium efflux and ROS generation provide additional activation signals[@halle2008].

Once activated, NLRP3 recruits ASC (apoptosis-associated speck-like protein) and procaspase-1, forming the inflammasome complex that autocatalyzes caspase-1 activation.

Downstream Effects

Activated caspase-1 cleaves pro-IL-1β and pro-IL-18 to their active forms, which are then released from the cell. The IL-1β produced is orders of magnitude more potent than that produced via NF-κB alone, creating powerful autocrine and paracrine inflammatory signaling[@fan2019].

In AD mouse models, genetic deletion of NLRP3 components reduces IL-1β levels, improves synaptic plasticity, rescues cognitive deficits, and reduces amyloid pathology — demonstrating the therapeutic potential of inflammasome inhibition.

ASC Specks and Propagation

Recent research shows that ASC specks — large protein aggregates released from NLRP3-activated cells — can propagate inflammasome activation to neighboring microglia, spreading the inflammatory response throughout connected brain networks[@kumar2024]. This provides a mechanism for the spreading of neuroinflammation that parallels the prion-like spread of misfolded proteins.

Astrocyte Reactivity in AD

Reactive Astrocytosis

[Astrocytes](/entities/astrocytes) undergo dramatic changes in AD, transitioning from a homeostatic to a reactive state[@liddelow2017]. Reactive astrocytes in AD adopt the A1 phenotype induced by activated microglia — characterized by upregulated complement component production (C3, C1q) and downregulated homeostatic functions.

Morphological changes: Hypertrophic cell bodies, extended processes, and upregulated GFAP (glial fibrillary acidic protein) expression. These changes are most prominent surrounding amyloid plaques and in regions of neuronal loss.

Functional changes: Reactive astrocytes release complement components that drive synaptic pruning, lose homeostatic functions (glutamate uptake, potassium buffering), and may acquire neurotoxic properties in the A1 state.

Astrocyte-Microglia Crosstalk

Bidirectional communication between astrocytes and microglia amplifies neuroinflammation:

Microglia release IL-1α, TNF-α, and C1q that induce A1 astrocyte formation
Reactive astrocytes release cytokines (IL-1β, IL-6, TNF-α) and chemokines (CCL2, CXCL1) that further activate microglia
Astrocyte-derived ATP is converted to adenosine, modulating microglial surveillance states

Astrocytic Phagocytosis and Aβ Clearance

Astrocytes contribute to Aβ clearance through phagocytosis and endocytic uptake, particularly in regions with limited microglial coverage. The MEGF10 and MERTK receptors mediate astrocytic phagocytosis of debris and Aβ[@iram2016]. Dysfunction of these pathways may contribute to accumulation of pathological aggregates. Astrocytes also produce matrix metalloproteinases (MMPs) that can degrade Aβ.

Blood-Brain Barrier Dysfunction

BBB Breakdown in AD

The [blood-brain barrier](/entities/blood-brain-barrier) is consistently disrupted in AD, facilitating peripheral immune cell infiltration and enabling toxic blood-borne substances to enter the brain parenchyma[@montagne2015]. Aβ directly damages endothelial cells and pericytes; inflammatory cytokines further compromise barrier integrity.

Tight junction proteins (claudin-5, occludin, ZO-1) show reduced expression and mislocalization in AD endothelial cells.

Pericytes — which regulate cerebral blood flow and BBB integrity — are particularly vulnerable in AD. Pericyte loss correlates with BBB breakdown and is observed early in disease progression. Pericyte deficiency in mouse models recapitulates key features of AD including neuroinflammation.

Perivascular and Subpial Glia Limitans

The glia limitans (perivascular and subpial glia limitans) forms a structural barrier between brain parenchyma and vascular/ventricular compartments. In AD:

Dysfunction allows increased peripheral immune cell infiltration
Breakdown enables toxic blood-borne substances to enter brain
Contributes to cerebral amyloid angiopathy (CAA) and hemorrhagic complications

Immune Cell Infiltration

BBB disruption allows peripheral immune cells to enter the brain parenchyma[@length2018]:

Monocytes: Enter AD brain and contribute to inflammatory responses and Aβ clearance; may be more effective at Aβ clearance than resident microglia in some contexts
CD8+ cytotoxic T cells: Most abundant T cell type in AD brains; may contribute to neuronal dysfunction
Regulatory T cells (Tregs): Typically reduced in AD, potentially limiting endogenous anti-inflammatory mechanisms

Neuroinflammation-Tau Interaction

Bidirectional Relationship

Neuroinflammation and tau pathology interact in a powerful bidirectional manner[@maphis2015]:

Inflammation drives tau pathology:

IL-1β enhances tau phosphorylation via GSK-3β and CDK5 activation
TNF-α promotes tau aggregation through kinase pathway activation
Microglial exosomes spread hyperphosphorylated tau between neurons
Chronic cytokine exposure accelerates NFT formation and spread

Tau pathology promotes inflammation:

NFT-bearing neurons release inflammatory signals (DAMPs)
Tau oligomers directly activate microglia through TLR2/TLR4
Neuronal death releases additional DAMPs that amplify inflammation
Tau propagation through connected networks spreads inflammatory activation

Microglial Exosome Spread

Microglia secrete exosomes containing hyperphosphorylated tau, inflammatory cytokines, complement components, and Aβ. These exosomes represent a mechanism for prion-like spreading of both pathological proteins and inflammatory signals throughout connected brain networks, potentially explaining the stereotyped progression of tau pathology through anatomically connected circuits.

TSPO PET Imaging of Microglial Activation

Translocator Protein Imaging

[TSPO PET imaging](/mechanisms/tspo-pet-imaging-neuroinflammation) allows in vivo visualization of microglial activation in AD patients[@kreisl2013]. TSPO (18 kDa translocator protein), formerly called the peripheral benzodiazepine receptor, is expressed primarily on the outer mitochondrial membrane of activated microglia. Increased TSPO binding in AD brains correlates with disease severity and cognitive decline.

First-generation TSPO ligands (e.g., [¹¹C]-PK11195) showed increased binding in AD, but high non-specific binding limited signal quality.

Second-generation ligands (e.g., [¹⁸F]-DPA-714, [¹¹C]-ER176) provide improved signal-to-noise ratios, though off-target binding in brain vasculature remains a concern.

Clinical Applications

TSPO PET has demonstrated[@cagnin2001]:

Increased microglial activation in MCI and AD patients vs. controls
Correlation between TSPO binding and cognitive impairment severity
Potential for monitoring therapeutic response in anti-inflammatory trials
Co-localization with amyloid PET burden in some studies

Novel TSPO ligands and alternative targets (e.g., P2X7 receptor, CSF1R) are in development for more specific imaging of distinct microglial activation states[@malhotra2023].

Therapeutic Strategies

Anti-Inflammatory Approaches

Given the central role of neuroinflammation in AD pathogenesis, numerous anti-inflammatory strategies have been explored[@heppner2015]:

NLRP3 inhibitors: Direct inflammasome blockade (MCC950, dapansutrile) shows efficacy in preclinical models; human trials are underway.

TREM2 agonists: Enhance microglial clearance function while potentially modulating inflammatory responses; antibody and gene therapy approaches in development.

CSF1R antagonists: Modulate microglial survival and activation state; depletion followed by repletion with beneficial microglia shows promise.

Anti-cytokine therapies: IL-1β antibodies (anakinra), TNF-α inhibitors have shown mixed results in clinical trials.

Minocycline: Broad microglial inhibitor; failed in clinical trials due to timing and specificity issues.

Challenges and Lessons Learned

Anti-inflammatory trials in AD have largely failed to date, with lessons including:

Late intervention may miss the therapeutic window
Broad immunosuppression can be harmful (immune surveillance functions)
Need for precise targeting of pathological inflammation vs. beneficial immune responses
Biomarker-guided patient selection required for trial success
The complexity of microglial states — some neuroprotective, some harmful — requires cell-type-specific approaches

Microglial Modulation Strategies

Rather than broadly suppressing microglial activation, emerging strategies aim to[@song2022]:

Enhance beneficial phagocytic capacity (TREM2 agonism)
Promote disease-suppressive phenotypes (CSF1R modulation)[@czirr2022]
Reduce excessive inflammatory mediator production (NLRP3 inhibition)
Support metabolic reprogramming of dysfunctional microglia

Mermaid Pathway Diagram

Mermaid diagram (expand to render)

Core Neuroinflammation Pages

[NLRP3 Inflammasome Pathway in AD](/mechanisms/nlrp3-inflammasome-ad-pathway) — detailed inflammasome mechanism
[TSPO PET Imaging for Neuroinflammation](/mechanisms/tspo-pet-imaging-neuroinflammation) — biomarker imaging
[Neuroinflammation in AD Pathway](/mechanisms/neuroinflammation-ad-pathway) — existing pathway page
[Microglia and Neuroinflammation](/mechanisms/microglia-neuroinflammation) — microglia-focused content

Gene and Protein Pages

[TREM2](/genes/trem2) — TREM2 gene and signaling
[CD33](/genes/cd33) — CD33 immunomodulatory receptor
[PLCG2](/genes/plcg2) — protective AD variant gene
[APOE](/proteins/apoe) — APOE and microglial function
[TYROBP (DAP12)](/entities/dap12) — TREM2 signaling adaptor

Cell Type Pages

[Microglia](/cell-types/microglia) — comprehensive microglia overview
[Disease-Associated Microglia](/mechanisms/disease-associated-microglia) — DAM state
[Astrocytes](/entities/astrocytes) — astrocyte biology

[Neuroinflammation Pathway](/mechanisms/neuroinflammation) — general neuroinflammation
[Complement System in Neurodegeneration](/mechanisms/complement-system-neurodegeneration) — complement cascade
[Blood-Brain Barrier Dysfunction](/mechanisms/blood-brain-barrier-dysfunction) — BBB mechanisms
[Neurovascular Unit](/mechanisms/neurovascular-unit) — neurovascular crosstalk
[Inflammasome Signaling in Neurodegeneration](/mechanisms/inflammasome-signaling-neurodegeneration) — inflammasome overview
[Cytokine Signaling in Neurodegeneration](/mechanisms/cytokine-signaling-neurodegeneration) — cytokine network

Disease Pages

[Alzheimer's Disease](/diseases/alzheimers-disease) — disease overview
[Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles) — tau pathology
[Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway) — amyloid pathology

Key Findings Summary

Neuroinflammation is a central AD driver, not merely a secondary response — supported by GWAS showing multiple immune-related AD risk genes

TREM2 variants (R47H and others) dramatically increase AD risk, demonstrating that microglial dysfunction is mechanistically causal

Microglial activation states (homeostatic, DAM, IFN-responsive, proliferative) are highly heterogeneous and context-dependent

Complement system mediates early synaptic loss through C1q/C3-dependent microglial synapse elimination

NLRP3 inflammasome amplifies IL-1β production and propagates inflammation via ASC specks

Bidirectional neuroinflammation-tau interaction creates feed-forward loops accelerating disease progression

BBB dysfunction enables peripheral immune infiltration, further amplifying brain inflammation

TSPO PET imaging enables in vivo monitoring of microglial activation as a biomarker and trial endpoint

Anti-inflammatory therapy failures highlight the need for precise, cell-type-specific targeting

Therapeutic strategies (TREM2 agonists, NLRP3 inhibitors, CSF1R modulation) are in development with promising preclinical data

slug	mechanisms-alzheimers-neuroinflammation
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e0381a19d670
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-alzheimers-neuroinflammation'}
_schema_version	1

📗 Cite This Artifact

Neuroinflammation in Alzheimer's Disease

Neuroinflammation in Alzheimer's Disease

Overview

Neuroinflammation in Alzheimer's Disease

Overview

Microglial Activation in Alzheimer's Disease

The Microglial Surveillance State

Pattern Recognition Receptors in AD

Disease-Associated Microglia (DAM)

APOE and Microglial Function

Phagocytic Dysfunction

TREM2 Signaling Pathways

TREM2 Structure and Ligands

Downstream Signaling Cascades

TREM2 Therapeutic Approaches

The Complement Cascade in AD

Classical Complement Activation

Microglial Synapse Elimination

Cytokine Network in AD Neuroinflammation

Pro-Inflammatory Cytokines

IL-1β and the Inflammasome Connection

The Cytokine Storm Concept

NLRP3 Inflammasome in AD

Inflammasome Activation by Aβ

Downstream Effects

ASC Specks and Propagation

Astrocyte Reactivity in AD

Reactive Astrocytosis

Astrocyte-Microglia Crosstalk

Astrocytic Phagocytosis and Aβ Clearance

Blood-Brain Barrier Dysfunction

BBB Breakdown in AD

Perivascular and Subpial Glia Limitans

Immune Cell Infiltration

Neuroinflammation-Tau Interaction

Bidirectional Relationship

Microglial Exosome Spread

TSPO PET Imaging of Microglial Activation

Translocator Protein Imaging

Clinical Applications

Therapeutic Strategies

Anti-Inflammatory Approaches

Challenges and Lessons Learned

Microglial Modulation Strategies

Mermaid Pathway Diagram

Cross-Linking to Related Pages

Core Neuroinflammation Pages

Gene and Protein Pages

Cell Type Pages

Related Mechanisms

Disease Pages

Key Findings Summary

See Also

💬 Discussion